drugset / Trial / NCT01110902
Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study will assess efficacy, safety and tolerability of 0.5 mg/day and 1 mg/day of sublingual (under the tongue) formulation of agomelatine in patients with Major Depressive Disorder. This study includes an 8-week double-blind phase.
Timeline
- Start
- 2010-05
- Primary completion
- 2011-06
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Agomelatine | Small molecule | 0.5 mg | Other |
| Subject | Agomelatine | Small molecule | 1 mg | Other |